Cargando…
A pain killer without analgesic tolerance designed by co-targeting PSD-95-nNOS interaction and α2-containning GABA(A)Rs
Overactivation of N-methyl-D-aspartate receptor (NMDAR) in the spinal cord dorsal horn (SDH) in the setting of injury represents a key mechanism of neuropathic pain. However, directly blocking NMDAR or its downstream signaling, interaction between postsynaptic density-95 (PSD-95) and neuronal nitric...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058733/ https://www.ncbi.nlm.nih.gov/pubmed/33897893 http://dx.doi.org/10.7150/thno.58364 |
_version_ | 1783681069850034176 |
---|---|
author | Li, Jun Zhang, Lin Xu, Chu Shen, Ying-Ying Lin, Yu-Hui Zhang, Yu Wu, Hai-Yin Chang, Lei Zhang, Ying-Dong Chen, Rong Zhang, Zheng-Ping Luo, Chun-Xia Li, Fei Zhu, Dong-Ya |
author_facet | Li, Jun Zhang, Lin Xu, Chu Shen, Ying-Ying Lin, Yu-Hui Zhang, Yu Wu, Hai-Yin Chang, Lei Zhang, Ying-Dong Chen, Rong Zhang, Zheng-Ping Luo, Chun-Xia Li, Fei Zhu, Dong-Ya |
author_sort | Li, Jun |
collection | PubMed |
description | Overactivation of N-methyl-D-aspartate receptor (NMDAR) in the spinal cord dorsal horn (SDH) in the setting of injury represents a key mechanism of neuropathic pain. However, directly blocking NMDAR or its downstream signaling, interaction between postsynaptic density-95 (PSD-95) and neuronal nitric oxide synthase (nNOS), causes analgesic tolerance, mainly due to GABAergic disinhibition. The aim of this study is to explore the possibility of preventing analgesic tolerance through co-targeting NMDAR downstream signaling and γ-aminobutyric acid type A receptors (GABA(A)Rs). Methods: Mechanical/thermal hyperalgesia were quantified to assess analgesic effects. Miniature postsynaptic currents were tested by patch-clamp recording to evaluate synaptic transmission in the SDH. GABA-evoked currents were tested on HEK293 cells expressing different subtypes of recombinant GABA(A)Rs to assess the selectivity of (+)-borneol and ZL006-05. The expression of α2 and α3 subunits of GABA(A)Rs and BDNF, and nNOS-PSD-95 complex levels were analyzed by western blotting and coimmunoprecipitation respectively. Open field test, rotarod test and Morris water maze task were conducted to evaluate the side-effect of ZL006-05. Results: (+)-Borneol selectively potentiated α2- and α3-containing GABA(A)Rs and prevented the disinhibition of laminae I excitatory neurons in the SDH and analgesic tolerance caused by chronic use of ZL006, a nNOS-PSD-95 blocker. A dual-target compound ZL006-05 produced by linking ZL006 and (+)-borneol through an ester bond blocked nNOS-PSD-95 interaction and potentiated α2-containing GABA(A)R selectively. Chronic use of ZL006-05 did not produce analgesic tolerance and unwanted side effects. Conclusion: By targeting nNOS-PSD-95 interaction and α2-containing GABA(A)R simultaneously, chronic use of ZL006-05 can avoid analgesic tolerance and unwanted side effects. Therefore, we offer a novel candidate drug without analgesic tolerance for treating neuropathic pain. |
format | Online Article Text |
id | pubmed-8058733 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-80587332021-04-23 A pain killer without analgesic tolerance designed by co-targeting PSD-95-nNOS interaction and α2-containning GABA(A)Rs Li, Jun Zhang, Lin Xu, Chu Shen, Ying-Ying Lin, Yu-Hui Zhang, Yu Wu, Hai-Yin Chang, Lei Zhang, Ying-Dong Chen, Rong Zhang, Zheng-Ping Luo, Chun-Xia Li, Fei Zhu, Dong-Ya Theranostics Research Paper Overactivation of N-methyl-D-aspartate receptor (NMDAR) in the spinal cord dorsal horn (SDH) in the setting of injury represents a key mechanism of neuropathic pain. However, directly blocking NMDAR or its downstream signaling, interaction between postsynaptic density-95 (PSD-95) and neuronal nitric oxide synthase (nNOS), causes analgesic tolerance, mainly due to GABAergic disinhibition. The aim of this study is to explore the possibility of preventing analgesic tolerance through co-targeting NMDAR downstream signaling and γ-aminobutyric acid type A receptors (GABA(A)Rs). Methods: Mechanical/thermal hyperalgesia were quantified to assess analgesic effects. Miniature postsynaptic currents were tested by patch-clamp recording to evaluate synaptic transmission in the SDH. GABA-evoked currents were tested on HEK293 cells expressing different subtypes of recombinant GABA(A)Rs to assess the selectivity of (+)-borneol and ZL006-05. The expression of α2 and α3 subunits of GABA(A)Rs and BDNF, and nNOS-PSD-95 complex levels were analyzed by western blotting and coimmunoprecipitation respectively. Open field test, rotarod test and Morris water maze task were conducted to evaluate the side-effect of ZL006-05. Results: (+)-Borneol selectively potentiated α2- and α3-containing GABA(A)Rs and prevented the disinhibition of laminae I excitatory neurons in the SDH and analgesic tolerance caused by chronic use of ZL006, a nNOS-PSD-95 blocker. A dual-target compound ZL006-05 produced by linking ZL006 and (+)-borneol through an ester bond blocked nNOS-PSD-95 interaction and potentiated α2-containing GABA(A)R selectively. Chronic use of ZL006-05 did not produce analgesic tolerance and unwanted side effects. Conclusion: By targeting nNOS-PSD-95 interaction and α2-containing GABA(A)R simultaneously, chronic use of ZL006-05 can avoid analgesic tolerance and unwanted side effects. Therefore, we offer a novel candidate drug without analgesic tolerance for treating neuropathic pain. Ivyspring International Publisher 2021-04-03 /pmc/articles/PMC8058733/ /pubmed/33897893 http://dx.doi.org/10.7150/thno.58364 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Li, Jun Zhang, Lin Xu, Chu Shen, Ying-Ying Lin, Yu-Hui Zhang, Yu Wu, Hai-Yin Chang, Lei Zhang, Ying-Dong Chen, Rong Zhang, Zheng-Ping Luo, Chun-Xia Li, Fei Zhu, Dong-Ya A pain killer without analgesic tolerance designed by co-targeting PSD-95-nNOS interaction and α2-containning GABA(A)Rs |
title | A pain killer without analgesic tolerance designed by co-targeting PSD-95-nNOS interaction and α2-containning GABA(A)Rs |
title_full | A pain killer without analgesic tolerance designed by co-targeting PSD-95-nNOS interaction and α2-containning GABA(A)Rs |
title_fullStr | A pain killer without analgesic tolerance designed by co-targeting PSD-95-nNOS interaction and α2-containning GABA(A)Rs |
title_full_unstemmed | A pain killer without analgesic tolerance designed by co-targeting PSD-95-nNOS interaction and α2-containning GABA(A)Rs |
title_short | A pain killer without analgesic tolerance designed by co-targeting PSD-95-nNOS interaction and α2-containning GABA(A)Rs |
title_sort | pain killer without analgesic tolerance designed by co-targeting psd-95-nnos interaction and α2-containning gaba(a)rs |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058733/ https://www.ncbi.nlm.nih.gov/pubmed/33897893 http://dx.doi.org/10.7150/thno.58364 |
work_keys_str_mv | AT lijun apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT zhanglin apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT xuchu apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT shenyingying apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT linyuhui apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT zhangyu apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT wuhaiyin apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT changlei apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT zhangyingdong apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT chenrong apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT zhangzhengping apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT luochunxia apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT lifei apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT zhudongya apainkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT lijun painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT zhanglin painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT xuchu painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT shenyingying painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT linyuhui painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT zhangyu painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT wuhaiyin painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT changlei painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT zhangyingdong painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT chenrong painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT zhangzhengping painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT luochunxia painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT lifei painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars AT zhudongya painkillerwithoutanalgesictolerancedesignedbycotargetingpsd95nnosinteractionanda2containninggabaars |